0001549595false00015495952023-11-012023-11-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 1, 2023

___________________________________________

NURIX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________

Delaware			001-39398			27-0838048
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(IRS Employer Identification No.)
1700 Owens Street, Suite 205 San Francisco, California						94158
(Address of Principal Executive Offices)						(Zip Code)

(415) 660-5320

(Registrant’s Telephone Number, Including Area Code) 

N/A

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			NRIX			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

---

Item 8.01    Other Events.

On November 1, 2023, Nurix Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has placed a partial clinical hold on the Company’s Phase 1 clinical trial evaluating NX-2127 for the treatment of various B-cell malignancies. Patients currently enrolled in the Phase 1 study who are deriving clinical benefit may continue to receive treatment in accordance with the ongoing study protocol; however, no additional patients may be enrolled until the partial clinical hold is resolved.

The partial clinical hold follows the Company’s communication to the FDA of its intention to transition to an improved manufacturing process. The Company’s other drug programs are not affected by the NX-2127 manufacturing process improvement.

A copy of the Company’s press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits

The following exhibits are filed herewith and this list is intended to constitute the exhibit index:

Exhibit No.						Exhibit Title or Description
99.1						Nurix Therapeutics, Inc. press release dated November 1, 2023.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NURIX THERAPEUTICS, INC.
Date: November 1, 2023			By:			/s/ Arthur T. Sands
						Arthur T. Sands, M.D, Ph.D.
						President and Chief Executive Officer

3